Aims and Objectives: Dipeptidyl peptidase-4 inhibitor (DPP4i) is widely used for the treatment of type 2 diabetes (T2DM) in several countries such as Japan, whereas biguanide (BG; mostly metformin) is recommended as a first-line antidiabetic medication in many countries according to evidence mainly from Western countries.
porter 2 inhibitor (SGLT-2i), have been sparse and be projected not to be performed since metformin is regarded as a de facto initial medical treatment for T2DM in many countries. It is important to confirm which drug is more appropriate as first-line oral medication in Japan and other East Asian countries as in the Western countries.
We investigated the difference in effectiveness and cost between BG and DPP4i using claims and medical check-up data in Japan. This information may be useful for revising current guidelines and may be applicable for other East Asian countries.
| METHODS
This is a secondary data analysis using claims and medical check-up data in Japan provided by the JMDC Inc. Japan has a system of universal health coverage, with almost 3500 insurers. The characteristics of a person (eg, age, region, and job) almost uniquely determine the insurance to participate. Employees and their dependents are insured by employer-sponsored health insurances. JMDC contracted with these insurers and collected their claims data to develop the JMDC Claims Database. 11 Employers are required to conduct medical check-ups for all employees to maintain employees' health. In addition, the Japanese government asks insurers to conduct the annual "special"
health check-ups in order to screen and prevent metabolic syndrome for those insured (both employees and their dependents) aged 40 to 74 years, at health care centre or hospitals/clinics. These two types of health check-ups are often combined when both are applicable.
Results of medical check-ups are captured by each insurer. According to the JMDC, participation rates of medical check-ups among employees aged 40 or older were quite higher (approximately 80%), whereas those among all of those insured including dependents and employees aged less than 40 were about 37%.
The design of data collection has been described previously. 11 In brief, the JMDC collected claims and medical check-up data for more than three million persons safely and anonymously. Because the subjects were employees or employers and their dependents, they included more men, healthy people, and young people (<75 years old).
| Study design
The design of the current study is shown in Figure 1 . The specific aim of this retrospective longitudinal study was to investigate the influence of the strategies of first-line antidiabetic drug on the effectiveness and cost of antidiabetic drugs thereafter, specifically compared between patients who were prescribed DPP4i or BG for T2DM. As
Japanese guideline does not specify a first-line antidiabetic drug and the inclination of the prescription is varied, in the beginning, we
showed the share of the first antidiabetic prescription to understand the background. Next, we included patients who had started their antidiabetic medication only with DPP4i or BG. In order to compare the two strategies about the first-line antidiabetic prescription (starting with DPP4i or BG), we included patients who had started with DPP4i or BG regardless of their medication change or interruption thereafter, as the inclusion criteria of an intention-to-treat randomized control trial should include all patients who started an allocated intervention regardless of whether or not they accomplished their treatment regimen or they discontinued on the way. We assessed the changes in HbA1c as the primary effectiveness and those in BMI as the secondary effectiveness, respectively, from the time of medical check-up before the first prescription to the time of medical check-up approximately 2 years after the first prescription.
We defined "cost" as the approximate annual cost of all antidiabetic medications used during the second year since the first prescription.
We also investigated the difference in the type (single or multiple) of antidiabetic medication approximately 2 years after the first prescription compared with the drug type at the first antidiabetic prescription.
For these purposes, we extracted information as explained below. 
| Participants
Patients who had information about their first prescription of antidiabetic medications, and baseline and follow-up medical check-ups were 
| Measurements
Timing of major measurements has been described in the study design section. Here, we briefly illustrate each variable used in the analyses.
Outcome variables were changes in HbA1c and BMI between baseline and follow-up medical check-ups and annual drug cost for all antidiabetic medications. For the drug cost, we converted Japanese yen into US$ according to the rate of 113 JPY per US$ based on December 14, 2017, exchange rates.
The type of the first antidiabetic medication prescribed was used as the main exposure variable. Among the patients, those who used DPP4i only (DPP4i group) and BG only (BG group) were included in the main analyses, while information on other prescription types was used only for descriptive analysis.
Covariates needed for propensity score matching were age on the day of the first prescription, sex, size of the medical facility where the first prescription was ordered, baseline HbA1c, baseline BMI, and calendar year of the first prescription. The type of subsequent antidiabetic medication (single or multiple) was also prepared as a secondary outcome information.
Regarding the source of information, prescription information and patients' characteristics were extracted from medical claims data, while only HbA1c and BMI values were derived from medical check-up data.
| Statistical analyses
We first described the characteristics of patients who received BG only or DPP4i only as the first antidiabetic prescription. Likewise, the characteristics of patients who received other types of drugs as the first prescription (categorized as sulfonylurea only, alphaglucosidase inhibitor only, thiazolidine only, glinide only, SGLT-2i only, multiple oral antidiabetic drugs, or fixed-dose oral combination drugs, and prescriptions, including at least a type of injection, such as insulin or glucagon-like peptide-1 agonist [GLP-1 agonist]) also were described for the purpose of reference.
Then types of DPP4i and BG and their dose were described at baseline. The type of subsequent antidiabetic medications (follow-up FIGURE 2 Flow chart of the study patient. HbA1c, haemoglobin A1c; DPP4i, dipeptidyl peptidase-4 inhibitor; BG, biguanide; SU, sulfonylurea; αGI, alpha glucosidase inhibitor; SGLT2 inhibitors, sodium glucose cotransporter 2 inhibitor; GLP-1 agonist, glucagon-like peptide-1 receptor agonist prescription) was also described according to the type of the first pre- analyses because these changes should be close to the effectiveness that physicians in clinics actually perceived when prescribing drugs based on patients' characteristics and knowledge about these drugs.
As additional information, we also described characteristics of patients who did or did not have medical check-ups and details of antidiabetic drugs in the two groups at follow-up.
Data on the descriptive tables were presented as the mean ± standard deviation (SD) or the number of patients (%). All tests were considered significant at P < .05. All statistical analyses were performed using Stata 15.0 software (StataCorp, College Station, Texas).
| RESULTS

Of 3 004 867 beneficiaries of insurances between January 2010 and
March 2016, 86 333 received antidiabetic medications. Among these patients, 5195 began antidiabetic medication use 1 year or later from the date of insurance entry and also had information on medical check-ups (characteristics of the patients who had or did not have a couple of medical check-up data were shown in Table S1 ). We excluded patients who met the following criteria: age < 20 or ≥ 70 years (n = 23), history of diabetes (n = 1576), HbA1c < 6.5%
(n = 808), hospitalized during the observation period (n = 900), and possible renal dysfunction (n = 310). In total, 2030 patients were included in this study, among which 1034 and 365 received DPP4i
and BG as their first antidiabetic prescription, respectively ( Figure 2 ). Abbreviations: BG, biguanide; BMI, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitor; HbA1c, haemoglobin A1c; PS, propensity score.
| HbA1c and BMI
Baseline characteristics are shown in Table S2 . Of patients who began diabetic treatment with DPP4i, 345 were propensity score matched to those who began with BG. The covariate balance in the matched cohort was improved considerably ( Table 1 ). The proportion of patients who had high HbA1c level was described in Table S5 . 
| Baseline and follow-up prescription
| Effectiveness and cost
Before propensity score matching, the change in HbA1c was significantly less and that in BMI was equivalent in the DPP4i group compared with Figure 3 ). In the stratified analyses by BMI category, the changes in HbA1c and BMI were not different between the two groups after propensity score matching. Annual cost for antidiabetic drugs was significantly higher in the DPP4i than in the BG groups; these results were almost the same as those of unstratified analyses and no apparent interaction was observed ( Figure S1 ).
| DISCUSSION
Our results demonstrated that DPP4i and BG had no difference in terms of effectiveness, whereas the cost was much higher in the Note. N (%). There are no patients who received both insulin and GLP-1 analog at the follow-up prescription.
Abbreviations: BG, biguanide; DM, diabetes mellitus; DPP4i, dipeptidyl peptidase-4 inhibitors; OAD, oral antidiabetic drug.
compared with metformin. [20] [21] [22] Regarding the prevention of complications induced by diabetes, it has been unclear whether DPP4i has superior effect on comorbidity prevention compared with BG. [23] [24] [25] Especially considering that East Asians may have a pathology of diabe- Our results also demonstrated a high retention rate of the antidiabetic medication used first in the patient. Actually, it also has been reported that the first-line antidiabetic medication, once prescribed, remains to be prescribed thereafter in England. 27 Evaluating influences on long-time cost is important to determine guidance regarding the first-line prescription as well. Our observational study used claims and medical check-up data and attempted to increase comparability using propensity score matching. Another characteristic of this study is that we classified patients according to the first antidiabetic medication prescribed to generate evidence about the first-line prescription.
This type of study may be useful for generating real-world evidence about the first-line prescription. Conversely, the study results may not be generalizable for other countries or long-term future because the price of the drug may change over time and the amount of medication used may change by time and/or country.
This study has several limitations. First, because these claims data were gathered from patients working for relatively large companies, most patients were male workers who did not change their companies during the observation periods. Also, we included neither patients who had renal dysfunction nor those with a recent history of admission. In the main analyses, we matched patients in the DPP4i group to those in the BG group using propensity score; the obtained effects should be applicable for population who tended to use metformin for the firstline antidiabetic medication (eg, younger age and greater BMI, shown in Table 1 ). As described above, we focus on patients who had information about their medical check-ups; in other words, we did not consider missingness for those who started diabetic medication but did not have their information about their medical check-ups. These may induce selection bias and/or reduce generalizability. We also conducted a multivariable regression analysis for sensitivity analysis, which indicated almost the same result as that of the propensity score matching. HbA1c decrease in the DPP4i group was slightly smaller compared with that in the BG group, although the difference was not a clinically important difference (0.14%, P = .043). The BMI change was not different level between the two groups; annual costs of antidiabetic drugs before the follow-up medical check-up was higher in the DPP4i group compared with the BG group (Table S4) . Although the result of the multivariable regression analysis may be applicable to more general population than that of the PS matching (only generalizable to those who were more likely to receive BG, that is, more male, middle-aged, and heavier in body weight), future studies would need to evaluate whether results of the present study are generalizable to other population. Second, HbA1c and BMI values were not measured just before the first prescription. Because these baseline data were extracted within 1 year before the first prescription (mean FIGURE 3 Therapeutic effectiveness and antidiabetic drug cost comparing the DPP4i and BG groups. Black bar indicates DPP4i group, and stripes bar indicates BG group. Of each bar graph, the left two and right two bars show the result before and after propensity score matching, respectively. DPP4i, dipeptidyl peptidase-4 inhibitor; BG, biguanide; HbA1c, haemoglobin A1c; BMI, body mass index; PS, propensity score
